News - Psychedelic Alpha

COMPASS Pathways’ key patents upheld by the US Patent and Trademark Office

Post published:June 6, 2023
Post category:Press Release

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

Post published:June 6, 2023
Post category:Press Release

Read more about the article Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed’s Phase 2B study evaluating MM-120

Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed’s Phase 2B study evaluating MM-120

Post published:June 5, 2023
Post category:Press Release

Read more about the article Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

Post published:June 5, 2023
Post category:Press Release

Read more about the article Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development milestones

Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development milestones

Post published:June 2, 2023
Post category:Press Release

Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Post published:June 2, 2023
Post category:Press Release

Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023

Post published:June 2, 2023
Post category:Press Release

atai Life Sciences to Participate in Upcoming June Investor Conferences

Post published:June 1, 2023
Post category:Press Release

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

Post published:June 1, 2023
Post category:Press Release

State of Kentucky Sets aside $42 Million for Psychedelic Research, with Focus on Ibogaine

Post published:May 31, 2023
Post category:News

Weekly Bulletin

Your weekly recap of news and analysis from the psychedelic sector.

Research Review

A monthly review of the most important psychedelics research.

News & Interviews

The latest news from across the psychedelics space.

Psychedelics Patent Trackers

We track the latest patents and filings related to psilocybin, MDMA and DMT.

Psychedelic Legalization & Decriminalization Tracker

Mapping psychedelic drug policy reform across the United States

Psychedelics Drug Development Tracker

From drug discovery to regulatory approval, we map drug development in psychedelics.

Stocks & Companies Directory

A directory of all the major psychedelics stocks, companies and ETFs.

Sector Landscape Map

Explore the Psychedelic Sector Landscape visually using our new tool.

Stock Watchlist

A one-stop overview of psychedelics stocks financial performance.

COMPASS Pathways’ key patents upheld by the US Patent and Trademark Office

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed’s Phase 2B study evaluating MM-120

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development milestones

Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023

atai Life Sciences to Participate in Upcoming June Investor Conferences

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

State of Kentucky Sets aside $42 Million for Psychedelic Research, with Focus on Ibogaine

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.